Traders bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Tuesday. $385.43 million flowed into the stock on the tick-up and $313.80 million flowed out of the stock on the tick-down, for a money net flow of $71.63 million into the stock. Of all stocks tracked, Johnson & Johnson had the 4th highest net in-flow for the day. Johnson & Johnson traded down ($1.22) for the day and closed at $130.54
JNJ has been the topic of a number of research analyst reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 target price on the stock in a research report on Wednesday, December 20th. JPMorgan Chase lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Wells Fargo reissued an “outperform” rating and issued a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Finally, Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $144.23.
The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $350,440.66, a price-to-earnings ratio of 17.88, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. During the same quarter in the prior year, the company earned $1.83 earnings per share. The company’s revenue was up 12.6% on a year-over-year basis. analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
In related news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.22% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. Goodman Financial Corp acquired a new position in Johnson & Johnson in the fourth quarter valued at $104,000. Harding Loevner LP acquired a new position in Johnson & Johnson in the second quarter valued at $106,000. Stelac Advisory Services LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $108,000. IHT Wealth Management LLC boosted its stake in Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new position in Johnson & Johnson in the second quarter valued at $124,000. 67.23% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/17/investors-buy-shares-of-johnson-johnson-jnj-on-weakness.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.